SEC Form 4 · accession 0001562180-19-001676
Akebia Therapeutics, Inc. · AKBA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicole R. Hadas
Officer — SVP, CLO & Secretary
Period of report
Feb 28, 2019
Accepted (ET)
Mar 5, 2019 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001517022
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 28, 2019 | A | 65,000 | $0.00 | A | 166,735 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to buy)F3 | $7.28 | Feb 28, 2019 | A | 100,000 | A | — | Feb 28, 2029 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date.
- F2Includes 451 shares of the Issuer's common stock purchased under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2018.
- F3The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.